Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Study to Evaluate the Effects of Neramexane on the Pharmacokinetics of a Combined Drospirenone/Ethinyl Estradiol Oral Contraceptive in Healthy Female Subjects

This study has been completed.
Sponsor:
Information provided by:
Merz Pharmaceuticals GmbH
ClinicalTrials.gov Identifier:
NCT00915174
First received: June 4, 2009
Last updated: May 5, 2011
Last verified: May 2011

June 4, 2009
May 5, 2011
June 2009
November 2009   (final data collection date for primary outcome measure)
Area Under Curve within a dose interval (AUC, 0-tau) and Maximum Plasma Concentration at Steady State (Cmax) of Drospirenone (DRSP) and Ethinyl Estradiol (EE) [ Time Frame: 24 hours ] [ Designated as safety issue: No ]
Pharmacokinetics [ Time Frame: drug concentration measurement over 24 hours ] [ Designated as safety issue: No ]
Complete list of historical versions of study NCT00915174 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Study to Evaluate the Effects of Neramexane on the Pharmacokinetics of a Combined Drospirenone/Ethinyl Estradiol Oral Contraceptive in Healthy Female Subjects
Not Provided

Primary:

To assess the effects of repeated dose of Neramexane on the steady-state pharmacokinetics of Drospirenone [DRSP] and Ethinyl Estradiol [EE]

Secondary:

To assess safety and tolerability of concomitant repeated dose treatments of Neramexane and a fixed-combinational DRSP- and EE-containing oral contraceptive [OC] (Yasmin®)

Not Provided
Interventional
Phase 1
Allocation: Randomized
Endpoint Classification: Pharmacokinetics Study
Intervention Model: Crossover Assignment
Masking: Double Blind (Subject, Investigator)
Healthy
Drug: Neramexane
25 mg q.d., 3 days 2 x 25 mg b.i.d., 11 days
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
36
November 2009
November 2009   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Healthy adult female subject of child bearing potential (including subject with tubal ligation), white origin, who is able to read, to write and fully understand German language
  • Aged 18 to 45 years (both inclusive)
  • BMI of 18-28 kg/m2 and a body weight of 50-90 kg (both inclusive)
  • The subject is required
  • To have taken a DRSP/EE- containing OC for at least two dosing cycles
  • To agree using reliable non hormonal birth control methods from Day -1 of study Period 1 until the Final Examination (e.g. non-hormonal IUD, double barrier method [e.g. condom with spermicide or diaphragm with spermicide], sexual abstinence). Women with tubal ligation or sterilized partner do not need an additional birth control method
  • Willing and able to provide written informed consent after having been informed of the requirements and the restrictions of the study

Exclusion Criteria:

  • History of clinically relevant allergy or known hypersensitivity to Neramexane/Memantine/ Amantadine and their derivatives
  • Hypersensitivity to Quinine
  • History of clinically relevant allergy or known hypersensitivity to any inactive ingredient in any of the used study medications (Neramexane, Yasmin®, Placebo) or tool substance
  • History of clinically relevant allergy or known hypersensitivity to DRSP/EE
  • Clinically relevant findings on the mammae or genital examination, PAP smear ≥ III
  • Any contraindications against the oral contraceptive:
  • present or past venous thromboses (deep vein thrombosis, pulmonary embolism);
  • present or past arterial thromboses (e.g. myocardial infarction) or their prodromal stages (e.g. angina pectoris and transitory ischaemic attack);
  • present or past cerebrovascular insult;
  • presence of a serious risk factor or several risk factors for an arterial thrombosis: diabetes mellitus with vascular changes, severe hypertension, severe lipid metabolism disturbance;
  • known or suspected genetic or acquired predisposition for venous or arterial thromboses like APC resistance,
  • known or suspected genetic lack of antithrombin III, lack of protein C, lack of protein S, hyperhomocysteinaemia and antiphospholipid antibodies (anticardiolipin antibodies, lupus anticoagulants);
  • present or past pancreatitis if this is accompanied by severe hypertriglyceridaemia;
  • present or past severe hepatic disease as long as the liver function tests have not normalized;
  • severe renal insufficiency or acute renal failure;
  • present or past hepatic tumors (benign or malign);
  • known or suspected sexual hormone dependent, malign tumors (e.g. of the genital organs or the mamma);
  • diagnostic not clarified vaginal bleedings;
  • anamnesis of migraine with focal neurologic symptoms;
  • known hereditary angioedema
  • Exposure to another investigational agent within the last two months before Day 1 of Period 1
Female
18 Years to 45 Years
Yes
Contact information is only displayed when the study is recruiting subjects
Germany
 
NCT00915174
MRZ 92579/TI/1005
Not Provided
Manager Public Disclosure, Merz Pharmaceuticals GmbH
Merz Pharmaceuticals GmbH
Not Provided
Study Director: Medical Expert MERZ Pharmaceuticals
Merz Pharmaceuticals GmbH
May 2011

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP